Carta al Director
Nutracéuticos (monacolina K, berberina y coenzima Q10) en pacientes con hipercolesterolemia moderada y un riesgo cardiovascular bajo-moderado. Potenciales beneficios de los tratamientos combinados
Nutraceuticals (monacolin K, berberine and coenzyme Q10) in patients with moderate hypercholesterolemia and low-moderate cardiovascular risk. Potential benefits of combined therapies
Leído
12170
Vecesse ha leído el artículo
983
Total PDF
11187
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 65 | 20 | 85 |
| 2025 11 | 488 | 98 | 586 |
| 2025 10 | 578 | 58 | 636 |
| 2025 9 | 516 | 54 | 570 |
| 2025 8 | 343 | 45 | 388 |
| 2025 7 | 393 | 21 | 414 |
| 2025 6 | 365 | 29 | 394 |
| 2025 5 | 305 | 19 | 324 |
| 2025 4 | 442 | 24 | 466 |
| 2025 3 | 764 | 72 | 836 |
| 2025 2 | 468 | 24 | 492 |
| 2025 1 | 428 | 12 | 440 |
| 2024 12 | 322 | 30 | 352 |
| 2024 11 | 411 | 32 | 443 |
| 2024 10 | 381 | 20 | 401 |
| 2024 9 | 365 | 24 | 389 |
| 2024 8 | 231 | 15 | 246 |
| 2024 7 | 355 | 21 | 376 |
| 2024 6 | 319 | 17 | 336 |
| 2024 5 | 296 | 23 | 319 |
| 2024 4 | 341 | 12 | 353 |
| 2024 3 | 230 | 171 | 401 |
| 2024 2 | 384 | 21 | 405 |
| 2024 1 | 265 | 18 | 283 |
| 2023 12 | 257 | 21 | 278 |
| 2023 11 | 370 | 12 | 382 |
| 2023 10 | 312 | 12 | 324 |
| 2023 9 | 290 | 12 | 302 |
| 2023 8 | 189 | 14 | 203 |
| 2023 7 | 248 | 6 | 254 |
| 2023 6 | 162 | 4 | 166 |
| 2023 5 | 169 | 12 | 181 |
| 2023 4 | 92 | 4 | 96 |
| 2023 3 | 22 | 6 | 28 |
| 2023 2 | 20 | 0 | 20 |
| 2022 1 | 1 | 0 | 1 |
| 2022 12 | 0 | 0 | 0 |
Mostrar todo
